fixed dose combination [Bioanalytics]

posted by avinash – India, 2015-03-06 12:18 (3779 d 11:08 ago) – Posting: # 14551
Views: 6,848

Dear Members,

Please let me know, If a fixed dose combination is administered during clinical phase of BA/BE study, where in, different methods are used for analysis; is it sufficient to check the specificity of the analyte in presence of other drug administered along with long term stability, or should a complete method validation is required with the analyte of interest in presence of other FDC drug in QC samples.

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,673 registered users;
40 visitors (0 registered, 40 guests [including 11 identified bots]).
Forum time: 00:27 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5